Prognosis of Patients Treated in a Single Neurosurgical Reference Centre for Brain Metastasis Caused by Dormant Disseminated Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2021 Apr 28

PMID 33907564

Citations 1

Authors

Lorenzo Ferlini

Lorenzo Peluso

Valentina Lolli

Nicolas Gaspard

Florence Lefranc

Affiliations

Soon will be listed here.

Abstract

Brain metastasis (BM) is a frequent complication of systemic cancer usually associated with poor prognosis. Survival depends on numerous factors, which complicates prognosis and treatment. It has been suggested that BM growing from previously dormant disseminated tumour cells (DTCs) may exhibit a milder phenotype than BM derived from continuously progressing metastatic cells; however, to the best of our knowledge, the prognosis of patients presenting with BM from dormant DTCs is unknown. The present study retrospectively compared survival data, collected from a single neurosurgical centre, between patients presenting with BM from previously dormant DTCs and patients with non-dormant BM. A total of 262 medical records were reviewed. In the univariate Cox regression analysis, the median survival of the dormant BM group was statistically longer than that of the non-dormant group (P=0.048); a trend towards a longer survival persisted after correcting for age, presence of breast cancer and treatment options (P=0.057), which are all factors known to influence outcome. The improved outcome of these patients could be considered in models for prognostication. Moreover, the development of therapies able to eradicate dormant DTCs could provide a new promising strategy to prolong the survival of patients with a favourable prognosis.

Citing Articles

Critical functions of extracellular matrix in brain metastasis seeding.

Yuzhalin A, Yu D Cell Mol Life Sci. 2023; 80(10):297.

PMID: 37728789 PMC: 10511571. DOI: 10.1007/s00018-023-04944-z.

References

Gao D, Nolan D, Mellick A, Bambino K, McDonnell K, Mittal V . Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008; 319(5860):195-8. DOI: 10.1126/science.1150224. View

Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky M . Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res. 2008; 10(5):R83. PMC: 2614518. DOI: 10.1186/bcr2152. View

Schardt J, Meyer M, Hartmann C, Schubert F, Schmidt-Kittler O, Fuhrmann C . Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell. 2005; 8(3):227-39. DOI: 10.1016/j.ccr.2005.08.003. View

Aguirre-Ghiso J, Liu D, Mignatti A, Kovalski K, OSSOWSKI L . Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001; 12(4):863-79. PMC: 32272. DOI: 10.1091/mbc.12.4.863. View

Lin X, DeAngelis L . Treatment of Brain Metastases. J Clin Oncol. 2015; 33(30):3475-84. PMC: 5087313. DOI: 10.1200/JCO.2015.60.9503. View

Chao S, Barnett G, Liu S, Reuther A, Toms S, Vogelbaum M . Five-year survivors of brain metastases: a single-institution report of 32 patients. Int J Radiat Oncol Biol Phys. 2006; 66(3):801-9. DOI: 10.1016/j.ijrobp.2006.05.015. View

Sosa M, Bragado P, Aguirre-Ghiso J . Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014; 14(9):611-22. PMC: 4230700. DOI: 10.1038/nrc3793. View

Giancotti F . Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155(4):750-64. PMC: 4354734. DOI: 10.1016/j.cell.2013.10.029. View

Gao H, Chakraborty G, Lee-Lim A, Mo Q, Decker M, Vonica A . The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012; 150(4):764-79. PMC: 3711709. DOI: 10.1016/j.cell.2012.06.035. View

10.

Kobayashi A, Okuda H, Xing F, Pandey P, Watabe M, Hirota S . Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55. PMC: 3244043. DOI: 10.1084/jem.20110840. View

11.

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

12.

Schulz M, Salamero-Boix A, Niesel K, Alekseeva T, Sevenich L . Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis. Front Immunol. 2019; 10:1713. PMC: 6667643. DOI: 10.3389/fimmu.2019.01713. View

13.

Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R . A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. DOI: 10.1056/NEJM199002223220802. View

14.

Lorger M, Felding-Habermann B . Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol. 2010; 176(6):2958-71. PMC: 2877856. DOI: 10.2353/ajpath.2010.090838. View

15.

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

16.

Retsky M, Demicheli R, Swartzendruber D, Bame P, Wardwell R, Bonadonna G . Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat. 1997; 45(2):193-202. DOI: 10.1023/a:1005849301420. View

17.

Goss P, Chambers A . Does tumour dormancy offer a therapeutic target?. Nat Rev Cancer. 2010; 10(12):871-7. DOI: 10.1038/nrc2933. View

18.

Soffietti R, Abacioglu U, Baumert B, Combs S, Kinhult S, Kros J . Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017; 19(2):162-174. PMC: 5620494. DOI: 10.1093/neuonc/now241. View

19.

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

20.

Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B . Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol. 2016; 127(3):407-14. DOI: 10.1007/s11060-016-2075-3. View